HOUSTON, Sept. 7, 2022 /PRNewswire/ -- Moleculin Biotech, Inc., ( Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.